Literature DB >> 11908705

Th1 and Th2 cytokine modulation by IL-10/IL-12 imbalance in autoimmune haemolytic anaemia (AIHA).

E Fagiolo1, C Toriani-Terenzi.   

Abstract

Recent studies about autoimmune diseases in animal models and in humans focused their attention on lymphocyte activation and in vitro cytokine production. The respective contribution of the Th1 and Th2 cytokines to the pathogenesis of autoimmune diseases is still a matter of debate. In this study the role of IL-2, IL-4, IFN-gamma, IL-10 and IL-12 cytokines were investigated by examining their spontaneous and mitogen-induced (OKT3 and PHA or LPS) synthesis and T-cells proliferative response by peripheral blood mononuclear cells to determine their role in the pathogenesis of AIHA. Thirteen patients affected by AIHA, idiopathic or associated with other diseases, and 13 healthy subjects, randomly selected from a group of blood donors, were investigated. This study indicated that AIHA is characterised by increased basal synthesis of IL-4 and decreased levels of IFN-gamma compared with healthy controls (p < 0,01). These results suggest that there is a basal decrease of Th1 cytokine and an increase of the Th2 ones. Enhanced IL-2 levels in AIHA patients are likely due to the necessity of a T-cell proliferation stimulus rather than produced as Th1 prevalent stimulation. Furthermore, it has been observed a significant increase in IL-12 production in LPS stimulated cultures from healthy controls, but not in AIHA patients, that shows IL-10 increased levels, which could cause a secondary decrease in IFN-gamma production and a stimulation of Th2 differentiation. These observations indicate that decreased production of Th1-type cytokines and prevalent Th2 ones leading to autoantibodies production in AIHA may be secondary to the imbalance between IL-10 and IL-12. These results strongly suggest that manipulation of the cytokine network, i.e. IL-10/IL-12 balance, maintained by cells of the innate immune system, can have a strong effect on the incidence of AIHA and their modulation might be useful for a therapeutic control of the disorder.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11908705     DOI: 10.1080/08916930290005891

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  5 in total

1.  Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia.

Authors:  K A Rogers; A S Ruppert; A Bingman; L A Andritsos; F T Awan; K A Blum; J M Flynn; S M Jaglowski; G Lozanski; K J Maddocks; J C Byrd; J A Woyach; J A Jones
Journal:  Leukemia       Date:  2015-10-07       Impact factor: 11.528

2.  CXCL13, CCL4, and sTNFR as circulating inflammatory cytokine markers in primary and SLE-related autoimmune hemolytic anemia.

Authors:  Boting Wu; Weiguang Wang; Yanxia Zhan; Feng Li; Shanhua Zou; Lihua Sun; Yunfeng Cheng
Journal:  J Transl Med       Date:  2015-04-08       Impact factor: 5.531

3.  Excessive Pro-Inflammatory Serum Cytokine Concentrations in Virulent Canine Babesiosis.

Authors:  Amelia Goddard; Andrew L Leisewitz; Mads Kjelgaard-Hansen; Annemarie T Kristensen; Johan P Schoeman
Journal:  PLoS One       Date:  2016-03-08       Impact factor: 3.240

4.  Characterisation of the Immunophenotype of Dogs with Primary Immune-Mediated Haemolytic Anaemia.

Authors:  James W Swann; Kelly Woods; Ying Wu; Barbara Glanemann; Oliver A Garden
Journal:  PLoS One       Date:  2016-12-12       Impact factor: 3.240

5.  Rapidly Exacerbating Autoimmune Hemolytic Anemia Together With Marked Cytokine Storm Triggered by Pneumonia Infection: A Case Report.

Authors:  Yuichiro Iwamoto; Takatoshi Anno; Katsumasa Koyama; Ryo Shirai; Hideaki Kaneto; Koichi Tomoda
Journal:  Front Immunol       Date:  2020-09-15       Impact factor: 7.561

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.